151 related articles for article (PubMed ID: 7911068)
1. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
[TBL] [Abstract][Full Text] [Related]
2. 2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.
Gollard R; Miller WE; Piro LD; Saven A
Leuk Lymphoma; 1997 Dec; 28(1-2):183-5. PubMed ID: 9498718
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
[TBL] [Abstract][Full Text] [Related]
4. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
6. The simultaneous occurrence of variant hairy cell leukemia and chronic-phase chronic myelogenous leukemia. A case report.
Reeves JE; Robbins BA; Pankey LR; Elias AL; Anderson WF
Cancer; 1995 Apr; 75(8):2089-92. PubMed ID: 7697598
[TBL] [Abstract][Full Text] [Related]
7. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
9. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine.
Robertson MJ; Tantravahi R; Griffin JD; Canellos GP; Cannistra SA
Am J Hematol; 1993 Jun; 43(2):95-102. PubMed ID: 8342558
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
Vahdat L; Wong ET; Wile MJ; Rosenblum M; Foley KM; Warrell RP
Blood; 1994 Nov; 84(10):3429-34. PubMed ID: 7949097
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
12. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Robak T; Góra-Tybor J
Neoplasma; 2001; 48(3):203-7. PubMed ID: 11583290
[TBL] [Abstract][Full Text] [Related]
13. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
14. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
[TBL] [Abstract][Full Text] [Related]
15. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
17. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.
Santana VM; Hurwitz CA; Blakley RL; Crom WR; Luo X; Roberts WM; Ribeiro R; Mahmoud H; Krance RA
Blood; 1994 Aug; 84(4):1237-42. PubMed ID: 7914104
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
Cortes JE; Talpaz M; Beran M; O'Brien SM; Rios MB; Stass S; Kantarjian HM
Cancer; 1995 Jan; 75(2):464-70. PubMed ID: 7812917
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
20. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
Saven A; Piro LD
Ann Intern Med; 1993 Aug; 119(4):278-83. PubMed ID: 8101069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
